Research and Markets (http://www.researchandmarkets.com/research/m72m99/medipoint)
has announced the addition of the "2014
Report on the US Predictive Breast Cancer Gene Testing Industry"
report to their offering.
The incidence of breast cancer is increasing due to the increased life
span and increasing adoption of Western lifestyle risk factors.
Predictive breast cancer gene tests can be used to identify women who
are at increased risk of developing hereditary breast cancer. The
Predictive Breast Cancer Gene Testing market has seen exponential growth
in the US, dominated by Myriad Genetics.
Gene testing in Europe is mostly carried out by the state funded health
sector, but increasingly private companies are offering breast cancer
gene tests to physicians. Myriad Genetics' position in the market is
dependent on it being the leading provider of the most common breast
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Competitive Assessment
5 Unmet Needs
6 Pipeline Products
7 Industry Overview
8 Current and Future Players
9 Market Drivers, Opportunities and Barriers
10 US Outlook and Forecasts
For more information visit http://www.researchandmarkets.com/research/m72m99/medipoint
[ Back To NFVZone's Homepage ]